Biggest News Aggregation in the World
📰 Nasdaq Dmac News

Page 2 - Nasdaq Dmac News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Nasdaq Dmac. Real-time updates on events, politics, business and more.

Head to Head Contrast: DiaMedica Therapeutics (NASDAQ:DMAC) and 9 Meters Biopharma (NASDAQ:NMTR)

DiaMedica Therapeutics (NASDAQ:DMAC – Get Rating) and 9 Meters Biopharma (NASDAQ:NMTR – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership. Analyst Ratings This is a breakdown of current […]
Kendyle Woodard Jayp Madan Meters Biopharma Inc Diamedica Therapeutics Inc Diamedica Therapeutics Get Rating

Analyzing 9 Meters Biopharma (NASDAQ:NMTR) and DiaMedica Therapeutics (NASDAQ:DMAC)

DiaMedica Therapeutics (NASDAQ:DMAC – Get Rating) and 9 Meters Biopharma (NASDAQ:NMTR – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation. Volatility & Risk DiaMedica Therapeutics has a beta […]
Kendyle Woodard Jayp Madan Diamedica Therapeutics Inc Meters Biopharma Inc Diamedica Therapeutics Get Rating

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Up 55.6% in March

DiaMedica Therapeutics Inc. (NASDAQ:DMAC – Get Rating) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 91,500 shares, an increase of 55.6% from the March 15th total of 58,800 shares. Based on an average daily trading volume, of 31,800 shares, […]
Davidj Wambeke Citadel Advisors Dimensional Fund Advisors Diamedica Therapeutics Inc Renaissance Technologies Diamedica Therapeutics Company Profile

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Insider David J. Wambeke Purchases 468,750 Shares

DiaMedica Therapeutics Inc. (NASDAQ:DMAC – Get Rating) insider David J. Wambeke purchased 468,750 shares of the company’s stock in a transaction dated Monday, April 10th. The stock was acquired at an average price of $1.60 per share, with a total value of $750,000.00. Following the completion of the transaction, the insider now owns 468,750 shares […]
Davidj Wambeke Citadel Advisors Catalyst Financial Partners Securities Exchange Commission Dimensional Fund Advisors Renaissance Technologies

DiaMedica Therapeutics (NASDAQ:DMAC) Posts Quarterly Earnings Results

DiaMedica Therapeutics (NASDAQ:DMAC – Get Rating) posted its quarterly earnings results on Tuesday. The company reported ($0.14) EPS for the quarter, hitting the consensus estimate of ($0.14), Yahoo Finance reports. During the same quarter in the previous year, the company earned ($0.10) EPS. DiaMedica Therapeutics Stock Performance DMAC stock opened at $1.52 on Wednesday. The […]
Dimensional Fund Advisors Citadel Advisors Renaissance Technologies Diamedica Therapeutics Company Profile Diamedica Therapeutics Inc Diamedica Therapeutics
Source: wkrb13.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

DiaMedica Therapeutics (DMAC) Set to Announce Earnings on Tuesday

DiaMedica Therapeutics (NASDAQ:DMAC – Get Rating) is scheduled to post its quarterly earnings results after the market closes on Tuesday, March 28th. Analysts expect DiaMedica Therapeutics to post earnings of ($0.14) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link. DiaMedica Therapeutics […]
Dimensional Fund Advisors Diamedica Therapeutics Company Profile Renaissance Technologies Citadel Advisors Diamedica Therapeutics Inc Diamedica Therapeutics

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Sees Significant Decrease in Short Interest

DiaMedica Therapeutics Inc. (NASDAQ:DMAC – Get Rating) saw a large drop in short interest during the month of May. As of May 31st, there was short interest totalling 51,000 shares, a drop of 50.3% from the May 15th total of 102,700 shares. Based on an average trading volume of 42,400 shares, the short-interest ratio is […]
Geode Capital Management Diamedica Therapeutics Company Profile Get Rating Stonepine Capital Management Dimensional Fund Advisors Diamedica Therapeutics Inc Diamedica Therapeutics

DiaMedica Therapeutics (NASDAQ:DMAC) Posts Earnings Results, Beats Estimates By $0.08 EPS

DiaMedica Therapeutics (NASDAQ:DMAC – Get Rating) released its quarterly earnings results on Monday. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.08, Fidelity Earnings reports. During the same period in the previous year, the business posted ($0.23) EPS. Shares of DMAC opened at $2.30 […]
Morgan Stanley Northern Trust Corp York Mellon Corp Zacks Investment Research Dimensional Fund Advisors Diamedica Therapeutics Inc

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science